Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Orenitram® (treprostinil) – Expanded indication
October 21, 2019 - United Therapeutics announced the FDA approval of Orenitram (treprostinil), for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.
